Micropharma Limited

Canada

Back to Profile

1-5 of 5 for Micropharma Limited Sort by
Query
Aggregations
IPC Class
A61K 9/50 - Microcapsules 3
C12N 1/20 - BacteriaCulture media therefor 3
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells 2
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate 2
A61M 35/00 - Devices for applying media, e.g. remedies, on the human body 2
See more
Found results for  patents

1.

INGESTIBLE MEDICAL DEVICE

      
Application Number CA2013000133
Publication Number 2013/120184
Status In Force
Filing Date 2013-02-15
Publication Date 2013-08-22
Owner MICROPHARMA LIMITED (Canada)
Inventor
  • Amoako-Tuffour, Yaw
  • Jones, Mitchell
  • Prakash, Satya

Abstract

Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub- unit with multiple chambers each having an opening for collecting or dispensing substances from the Gl tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.

IPC Classes  ?

  • A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
  • A61B 5/07 - Endoradiosondes
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
  • G01D 5/12 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means
  • G01D 5/26 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using optical means, i.e. using infrared, visible or ultraviolet light
  • G08C 17/02 - Arrangements for transmitting signals characterised by the use of a wireless electrical link using a radio link
  • G08C 23/04 - Non-electric signal transmission systems, e.g. optical systems using light waves, e.g. infrared

2.

EPSILON-POLY-LYSINE CAPSULES

      
Application Number CA2010002057
Publication Number 2011/075848
Status In Force
Filing Date 2010-12-22
Publication Date 2011-06-30
Owner MICROPHARMA LIMITED (Canada)
Inventor
  • Martoni, Christopher John
  • Jones, Mitchell Lawrence
  • Prakash, Satya

Abstract

The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.

IPC Classes  ?

  • B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/56 - Materials from animals other than mammals
  • A61K 35/66 - Microorganisms or materials therefrom
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 9/50 - Microcapsules
  • A61L 27/38 - Animal cells
  • C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
  • C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
  • C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes

3.

BACTERIAL COMPOSITIONS FOR PROPHYLAXIS AND TREATMENT OF DEGENERATIVE DISEASE

      
Application Number CA2010000660
Publication Number 2010/124387
Status In Force
Filing Date 2010-04-30
Publication Date 2010-11-04
Owner MICROPHARMA LIMITED (Canada)
Inventor
  • Prakash, Satya
  • Jones, Mitchell, Lawrence
  • Martoni, Christopher

Abstract

The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50µmol glycodeoxycholic acid (GDCA)/gram/hour and >2µmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 µmol GDCA/g/hr and >7 µmol TDCA/g/hr when measured over 30 minutes.

IPC Classes  ?

  • A61K 35/74 - Bacteria
  • A61K 9/50 - Microcapsules
  • A61K 9/51 - Nanocapsules
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/04 - AnorexiantsAntiobesity agents
  • A61P 3/06 - Antihyperlipidemics
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • C12N 1/04 - Preserving or maintaining viable microorganisms
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
  • C12N 11/02 - Enzymes or microbial cells immobilised on or in an organic carrier
  • C12N 11/04 - Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres

4.

NITRIC OXIDE COMPOSITIONS AND DEVICES AND METHODS FOR COSMESIS

      
Application Number CA2009000859
Publication Number 2009/155690
Status In Force
Filing Date 2009-06-23
Publication Date 2009-12-30
Owner MICROPHARMA LIMITED (Canada)
Inventor
  • Prakash, Satya
  • Jones, Mitchell, Lawrence

Abstract

The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis.

IPC Classes  ?

  • C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
  • A61K 8/11 - Encapsulated compositions
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/66 - Enzymes
  • A61K 8/72 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
  • A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
  • A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
  • A61Q 19/00 - Preparations for care of the skin
  • C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
  • C12M 1/40 - Apparatus specially designed for the use of free, immobilised, or carrier-bound enzymes, e.g. apparatus containing a fluidised bed of immobilised enzymes
  • C12N 1/16 - YeastsCulture media therefor
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
  • C12N 9/10 - Transferases (2.)
  • C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
  • C12N 9/50 - Proteinases
  • C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide

5.

NITRIC OXIDE DEVICE AND METHOD FOR WOUND HEALING, TREATMENT OF DERMATOLOGICAL DISORDERS AND MICROBIAL INFECTIONS

      
Application Number CA2009000858
Publication Number 2009/155689
Status In Force
Filing Date 2009-06-23
Publication Date 2009-12-30
Owner MICROPHARMA LIMITED (Canada)
Inventor
  • Prakash, Satya
  • Jones, Mitchell, Lawrence

Abstract

The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products.

IPC Classes  ?

  • C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
  • A23B 4/16 - Preserving with chemicals not covered by groups or in the form of gases, e.g. fumigationCompositions or apparatus therefor
  • A23B 4/22 - MicroorganismsEnzymes
  • A23L 1/272 - Retaining or modifying natural colour by use of additives, e.g. optical brighteners (A23L 1/275 takes precedence);;
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 38/43 - EnzymesProenzymesDerivatives thereof
  • A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K 9/50 - Microcapsules
  • A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
  • C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
  • C12M 1/40 - Apparatus specially designed for the use of free, immobilised, or carrier-bound enzymes, e.g. apparatus containing a fluidised bed of immobilised enzymes
  • C12N 1/16 - YeastsCulture media therefor
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
  • C12N 9/10 - Transferases (2.)
  • C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
  • C12N 9/50 - Proteinases
  • C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide